

SmartTab To Present at Biopharm America 2020 Digital International Partnering Conference

Pioneers of Ingestible Wireless Drug Delivery Platform Continue to Make Waves in Pharmaceutical Industry

Smarttab THE FUTURE OF DIGITAL MEDICINE

DENVER, COLORADO, USA, September 17, 2020 /EINPresswire.com/ -- FOR IMMEDIATE RELEASE Event Date: Starting September 9, 2020, (OnDemand 24/7)

SmartTab, a digital medicine company developing innovative wireless drug delivery systems that address significant unmet medical needs, announced today that Founder and CEO, Robert

"

InjectTab will revolutionize the treatment of selfinjections with an ingestible capsule that delivers biologics, large molecules, and proteins internally to the stomach or upper GI areas"

Robert Niichel

Niichel, will present at BioPharm America's Annual International Partnering Conference. This life sciences partnering conference draws innovative leaders across biotech, finance, and pharma providing access to cuttingedge technologies and new potential therapies and cures through industry presentations, networking sessions and pre-scheduled partnering meetings. The conference presentations are already live on BioPharm America's website and meetings will be held September 21-24, 2020.

"Presenting at BioPharm America is a great way to share

our progress as we expand in 2020 and work toward successful animal studies of InjectTab," says Niichel. "We will continue the momentum into 2021 with a focus on human clinical studies for TargetTab. On a mission to bring Patient-Centered Drug Delivery Systems to market."

Niichel will present an expansion of the drug delivery platform, InjectTab. "InjectTab will revolutionize the treatment of self-injections with an ingestible capsule that delivers biologics, large molecules, and proteins internally to the stomach or upper GI areas," says Niichel. "This advancement will allow painful injections via syringe and needle to be replaced by swallowing a capsule that injects active ingredients into the lining of the stomach, where there are little to no

pain receptors."

This presentation follows a successful PK Pre-Clinical Animal study last year that demonstrated a Proof-of-Concept working model of TargetTab. According to the results from the TargetTab PK Pre-Clinical Animal Study and the pharmacokinetic profiles, the capsule achieved actuation and released active ingredients when receiving the wireless communication signal. The findings validated that the capsule is capable of receiving wireless power and monitoring signals from the external source to delivery and active ingredient in a targeted area. A pill that painlessly releases medication when and where it's needed in the body will soon be available to the public.

□Robert Niichel will present the Wireless Ingestible Capsule at BioPharm America 2020 September 9 here: □□<u>https://informaconnect.com/biopharm-america-</u> virtual/agenda/2/#biopharm-america-presentations_smarttab

About SmartTab:SmartTab has developed a personalized wireless drug delivery platform comprised of an ingestible capsule with a microprocessor, proprietary smart polymer actuator, and active ingredients. We're on a mission to provide novel, effective therapies that improve patient outcomes and compliance. <u>smarttab.co/</u>

About Biopharm America and the Annual International Partnering Conference: <u>informaconnect.com/biopharm-america/</u>

Sacha Heppell SmartTab +1 720-220-4152 email us here

This press release can be viewed online at: https://www.einpresswire.com/article/526412047

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire[™], tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2020 IPD Group, Inc. All Right Reserved.